Rheumatoid arthritis cohort biorepository

Overview

About this study

The purpose of this study is to create a biobank with a linked database including medical data and biospecimens from adult (>18 years) patients with rheumatoid arthritis (RA) and individuals with positive cyclic citrullinated peptide antibodies (anti-CCPantibodies) who do not yet meet classification criteria for RA (i.e. pre-RA), as well as comparators without RA.  We propose to recruit and enroll 1,500 participants with RA and pre-RA and 1500 participants without RA.  

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion criteria:

  • Resident of the United States (to make it possible to conduct future subject follow-up using the National Death Index)
  • Age 18 years or older.
  • Able to provide informed consent.
  • Has a Mayo Clinic or affiliated Health Systems ID.

Exclusion criteria:

  • Institutionalized (i.e., Federal Medical Prison)
  • Individuals who do not comprehend English or Spanish (i.e., participants must be able to read and sign a consent form in English or Spanish without the assistance of an interpreter)
  • Individuals who are unable to sign consent (e.g., mentally challenged, those declared legally incompetent).

Additional exclusion criteria for those undergoing tissue sampling (i.e., synovial biopsy, adipose tissue sampling):

  1. Ongoing or suspected infection, acute or chronic, particularly local skin/soft tissue infection at potential biopsy sites
  2. Ongoing antibiotic use
  3. Anemia (female subjects hemoglobin of <11 g/dl and male subjects hemoglobin <12 g/dl)
  4. Active coronary artery disease or history of unstable macrovascular disease (unstable angina, myocardial infarction, stroke, and revascularization of coronary, peripheral or carotid artery within 3 months of recruitment)
  5. Renal failure (serum creatinine > 1.5mg/dl)
  6. Chronic active liver disease (AST>144 IU/L or ALT>165 IU/L)
  7. Oral warfarin group medications or history of blood clotting disorders
  8. Pregnancy or breastfeeding
  9. Cancer on active treatment

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/27/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Elena Myasoedova, M.D., Ph.D.

Contact us for the latest status

Contact information:

Department of Rheumatology Research Unit

(507) 422-6732

More information

Publications

Publications are currently not available
.
CLS-20579862

Mayo Clinic Footer